ACE and angioedema: Importantly, this is the main reason that development of a dual ACE/neprilysin inhibitor omapatrilat was halted, because the use of this drug was associated with considerably higher incidence of angioedema in patients with cardiovascular disorders (Campbell, 2018; Sulpizio et al., 2005).